1793 completed, 264 unknown, 153 recruiting, 112 terminated. 521 Phase 2, 512 Phase 1, 447 Not applicable, 406 Phase 3, 275 Phase 4.
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings Factory-treated lesu, Soaked lesu, Untreated lesu - Malaria (Plasmodium Falciparum), Malaria Incidence | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 1350 | 2027-09-01 | 2026-10-29 |
| Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal | Not applicable | Recruiting | Centre Hospitalier Universitaire de la Réunion | 60 | 2027-08-01 | 2026-09-15 |
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria Coartem® Baby - Malaria | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 20 | 2027-06-18 | 2026-07-20 |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study. Hydroxychloroquin, Placebo, Doxycycline - Lyme Borreliosis, Nervous System | Phase 4 | Not yet recruiting | Radboud University Medical Center | 50 | 2027-03-01 | 2026-08-27 |
| Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | Sanaria Inc. | 45 | 2027-03-01 | 2026-07-31 |
| Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea Spatial emanator outdoor, Spatial emanator indoor - Malaria | Not applicable | Not yet recruiting | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 4350 | 2027-02-01 | 2026-11-10 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Insecticide-Treated Baby Wraps for the Prevention of Malaria Permethrin-treated lesu, Etofenprox-treated lesu, Untreated lesu - Malaria (Plasmodium Falciparum), Malaria Incidence | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 1296 | 2027-01-01 | 2026-08-19 |
| Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis | Phase 3 | Not yet recruiting | Institute of Tropical Medicine, Belgium | 900 | 2027-01-01 | 2026-03-10 |
| Immersive Technology Headsets to Reduce Procedural Pain and Anxiety: Feasibility and Effects in Cutaneous Leishmaniasis Patients in Pakistan Virtual Reality - Cutaneous Leishmaniasis, Pain | Not applicable | Not yet recruiting | Stanford University | 15 | 2027-01-01 | 2026-10-05 |
| Mast Cell Treatment in Post-tick Bite Illness (PTBI) Ketotifen, fexofenadine, Cromolyn Sodium - Tick Bites, Mast Cell Activation Disorders | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 50 | 2027-01-01 | 2026-11-09 |
| An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health Nifurtimox (BAYA2502) - Chagas Disease | Not yet recruiting | Bayer | 50 | 2026-12-31 | 2026-07-06 | |
| Integrating the Guardian Spatial Emanator Within AVENIR II Spatial Emanator - Malaria | Not applicable | Not yet recruiting | University of California, San Francisco | 150000 | 2026-12-01 | 2026-07-22 |
| Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. Plague, Bubonic; Plague, Skin | Not yet recruiting | Institute of Tropical Medicine, Belgium | 300 | 2026-12-01 | 2026-09-29 | |
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan - Healthy Volunteer, Malaria | Not applicable | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2026-11-17 | 2026-11-12 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-17 | 2026-11-12 |
| Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 750 | 2026-11-17 | 2026-11-12 |
Showing 20 of 2564. Sign in to see all of them.
Malaria (1138) · Malaria, Falciparum (451) · Dengue (275) · Malaria, Vivax (124) · Leishmaniasis, Cutaneous (102) · Lyme Disease (96) · Chikungunya Fever (88) · Schistosomiasis (78) · Zika Virus Infection (77) · Chagas Disease (73) · Anemia (72) · Encephalitis, Japanese (72) · Leishmaniasis (71) · Severe Dengue (65) · Leishmaniasis, Visceral (61)
Infections (2522) · Mosquito-Borne Diseases (1936) · Parasitic Diseases (1788) · Protozoan Infections (1675) · RNA Virus Infections (637) · Virus Diseases (636) · Arbovirus Infections (573) · Flaviviridae Infections (502) · Flavivirus Infections (490) · Hemorrhagic Fevers, Viral (328) · Euglenozoa Infections (300) · Pathological Conditions, Signs and Symptoms (282) · Malaria (244) · Nervous System Diseases (210)
Artemether, Lumefantrine Drug Combination (165) · fanasil, pyrimethamine drug combination (99) · Primaquine (92) · Chloroquine (89) · Artesunate (74) · Amodiaquine (57) · miltefosine (39) · amodiaquine, artesunate drug combination (38) · Saline Solution (35) · tafenoquine (34) · Azithromycin (33) · Blood Specimen Collection (32) · Ivermectin (32) · Praziquantel (31) · Doxycycline (30)
National Institute of Allergy and Infectious Diseases (NIAID) (215) · University of Oxford (143) · London School of Hygiene and Tropical Medicine (119) · U.S. Army Medical Research and Development Command (82) · GlaxoSmithKline (60) · Medicines for Malaria Venture (59) · Sanofi Pasteur, a Sanofi Company (49) · Institute of Tropical Medicine, Belgium (43) · Pfizer (40) · Centers for Disease Control and Prevention (39) · University of California, San Francisco (36) · Drugs for Neglected Diseases (35) · PATH (31) · Novartis Pharmaceuticals (29) · Sanaria Inc. (29)
United States (378) · Brazil (137) · Kenya (132) · Uganda (129) · Burkina Faso (122) · Mali (108) · Tanzania (99) · Thailand (99) · United Kingdom (84) · Colombia (74) · France (72) · Ghana (70) · India (57) · Democratic Republic of the Congo (55) · Ethiopia (48)
Anna Durbin, MD (31) · Patrick E Duffy, M.D. (14) · Shyam Sundar, MD (9) · Adriana R Marques, M.D. (8) · Grant Dorsey, MD, PhD (8) · Kassoum Kayentao, MD, MPH, PhD (7) · Rick M Fairhurst, M.D. (7) · Salim Abdulla, MD, PhD (7) · Teun Bousema, PhD (7)
PMID 39324693, PMID 40099800, PMID 23433102, PMID 34585740, PMID 25421474, PMID 26666916, PMID 39787798, PMID 42253092, PMID 26214039, PMID 28081133, PMID 29897841, PMID 33822015, PMID 39377226, PMID 11873261, PMID 22610930, PMID 26383952, PMID 26571311, PMID 28193647, PMID 28379954, PMID 28495354, PMID 29217375, PMID 30075748, PMID 31878895, PMID 31932368, PMID 32228663, PMID 33289099, PMID 35664997, PMID 35709798, PMID 35945599, PMID 36534705, PMID 37790581, PMID 38115002, PMID 38418982, PMID 39116904, PMID 40245769, PMID 41014333, PMID 41176969, PMID 42848323, PMID 10656038, PMID 16928995, PMID 18828899, PMID 19150418, PMID 19558654, PMID 19641203, PMID 2022660, PMID 20934459, PMID 21298114, PMID 21443960, PMID 21592984, PMID 21849081
2014 (8), 2016 (8), 2019 (8), 2015 (6), 2023 (6), 2018 (5), R01HD068174 (4), 2009 (3), 2025 (3), R01AI141444 (3), U19AI065866 (3), 2008 (2), P01HD059454 (2), R01AI110478 (2), R01NS074409 (2)